Methyl-β-cyclodextrin, a cyclic oligosaccharide know n for its interaction w ith the plasm a m em brane induces several events in cells including cell growth and anti-tum or activity. In this study, w e have investigated the possible role of cyclooxygenase 2 (COX-2) in cell growth arrest induced by m ethyl-β-cyclodextrin in Raw264.7 macrophage cells. M ethyl-β-cyclodextrin inhibited cell grow th and arrested the cell cycle, and this cell cycle arrest reduced the population of cells in the S phase, and concom itantly reduced cyclin A and D expressions. M ethyl-β-cyclodextrin in a dose-and tim e-dependent manner, also induced COX-2 expression, prostaglandin E 2 (PG E 2 ) synthesis, and CO X-2 prom oter activity. Pretreatm ent of cells w ith NS398, a CO X-2 specific inhibitor com pletely blocked PG E 2 synthesis induced by m ethyl-β-cyclodextrin, how ever inhibition on cell proliferation and cell cycle arrest w as not effected, suggesting nonas so cia tio n o f C O X -2 in th e ce ll cy cle arres t. These results suggest that m ethyl-β-cyclodextrin induced cell growth inhibition and cell cycle arrest in Raw 264.7 cells m ay be m ediated by cyclin A and D1 expression.
Introduction
Cyclodextrins are known for their ability to modify the physico-pharmaceutical properties of various drugs and components through inclusion complex formation. This inclusion of the drug may have several advantages, i.e., increased aqueous solubility and stability, and a reduction in undesirable side effects (Loftsson et al., 2001) . Methyl-β-cylodextrin is able to potentiate the in vitro anti-tumoral activity of doxorubicin in several sensitive cell lines (Grosse et al., 1998) . Several studies have shown some cyclodextrins, including methyl-β-cyclodextrin, have unique cellular activities in terms of its interaction with the plasma membrane, permeabilization or hemolytic activity (Hirayama et al., 1990; Loftsson et al., 2002; Nagase et al., 2002) . Methyl-β-cyclodextrin is considered as an interesting candidate for experimental cancer treatment because of its relatively low toxicity, unlike di-and tri-methyl-β-cyclodextrin (Grosse et al., 1999) .
Cyclooxygenase (COX) catalyzes the first ratelimiting step in the formation of prostaglandin and thromboxane eicosanoids from phospholipase A2 released arachidonic acid (van der Donk et al., 2002) . It is also known as prostaglandin endoperoxide H synthase, COX is responsible for both the cyclooxygenase reaction, in which arachidonic acid is converted to prostaglandin G2 (PGG2), and the peroxidase reaction, in which this intermediate undergoes a bi-electron reduction to PGH2 (Kiefer et al., 2000) . Two forms of COX have been identified, which are encoded by distinct genes, but which exhibit structural and enzymatic similarities. COX-2 is normally not expressed in cells, but is rapidly induced to produce in response to a wide variety of cytokines, and growth factors. COX-2 is an important target in the treatment of arthritis, pain, and possibly cancer (Turini et al., 2002) . Moreover, the expression of COX-2 is increased in inflamed tissues such as, the rheumatoid synovium, and selective COX-2 inhibitors are useful for the treatment of arthritis (Crofford, 1999) . COX-2 is also overexpressed in transformed cells and in tumors (Dannenberg et al., 2001) . Although chemopreventive strategies have focused on inhibitors of COX enzyme activity, the mechanism of COX-2 inhibition with anticancer activity is still well understood (Mestre et al., 1999) . Moreover, selective COX-2 inhibitors have been found to prevent the formation of intestinal and skin tumors in experimental animals (Pentland et al., 1999) . Thus, it is reasonable to posMethyl-β-cyclodextrin inhibits cell growth and cell cycle arrest via a prostaglandin E 2 independent pathway 1 tulate that compounds, which induce COX-2 expression could predispose neoplsia.
COX-derived PGE2 have been shown to exert many biological properties such as the induction of inflammation, the maintenance of kidney function and the modulation of the immune response (DuBoise et al., 1998) . Moreover, PGE2 can modulate the proliferation of cells including fibroblasts, macrophages and some types of malignant cells (Harris et al., 2002) . Earlier studies have suggested that PGE2 can promote the proliferation in various cell types including glandular epithelial cell, colorectal carcinoma cell (Sheng et al., 2001; Buchanan et al., 2003) . However, other reports showed anti-proliferative action of PGE2 (Belvisi et al., 1998; Keerthisingam et al., 2001 ).
The present study was undertaken to assess the effect of methyl-β-cyclodextrin on the growth of cells and their production of PGE2, and to determine the relationship between cell growth and PGE2 production in macrophages. We found that methyl-β-cyclodextrin induced cell growth inhibition and the cell cycle arrest via cyclin A and D regulation and in a dose-and timedependent manner, stimulated the expression of COX-2 protein, and PGE2 production independent of cell cycle arrest and cell growth inhibition effect. C ell n u m b er co u n tin g an d th ym id in e up take m easurem en t Raw264.7 cells were grown in 12-well plates at a concentration of 5×10 5 cells/well, and then [ 3 H]thymidine (0.4 µCi/well) was added for 4 h. The plates were washed with PBS 12 h later, and scintillation fluid was added for the DNA synthesis assay and radioactivity quantified in a scintillation counter. For counting viable cell numbers, trypan blue was added to the cells at a 1:1 dilution, and cells were counted using a hemocytometer.
M aterials and M ethods
D eterm in atio n o f P G E 2 prod uctio n PGE2 production was measured using a commercial PGE2 enzyme immunoassay (EIA) kit. Cells were cultured in 6-well plates and stimulated with methyl-β-cyclodextrin. Supernatant samples were obtained at the indicated doses or times and subjected to EIA analysis.
T ran sfection and prom o ter activity assay
The COX-2 promoter DNA with full-length (-1432/+59 bp) was constructed into pGL2 vector. Cells were transfected with COX-2 promoter DNA using Lipofectamine 2000. After transfection, cells were incubated in complete media for 24 h at 37 o C before being stimulated with methyl-β-cyclodextrin for 12 h at 37 o C. Cell lysates were assayed for luciferase activity according to the manufacture's instructions (Promega) using a luminometer.
P ro tein extraction an d W estern b lot analysis
Cells were washed twice in cold PBS and lysed on ice using lysis solution (1% Triton X-100, 50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM PMSF, 1 mM Na3VO4, and protease inhibitor cocktail). Sample protein concentrations were determined using the Bio-Rad protein assay. Proteins from the cell lysates (30 µg) were boiled at 95 o C in Laemmli SDS loading buffer, separated on 8% SDS-PAGE, and electrotransferred to nitrocellulose membranes. The membranes were then blocked for at least 30 min at room temperature in Tris buffered saline-0.05% Tween-20 (TTBS) containing 5% non-fat dry milk, and then incubated with TTBS containing the primary antibody. For immunoblotting of COX-2, incubated for 4 h at room temperature. After 5 washes of 30 min each in TTBS, the membranes were incubated with peroxidase-conjugated secondary antibody for 1 h. After 5×30 min washes with TTBS, enhanced chemiluminescence detection (Amersham) was performed and the membranes were exposed to X-ray films.
F low cyto m etry cell cycle an alysis
After methyl-β-cyclodextrin treatment, cells were washed with PBS, trypsinized, fixed with 70% ethanol, and stored at -20 o C. Cells were then stained for 30 min at room temperature with a 20 µg/ml PI solution in PBS containing 0.1% Triton X-100 and 0.2 mg/ml DNase-free RNase A. Cells were analyzed on a FACS flow cytometer (Becton Dickenson, Mountain 1 View, CA). At least 10,000 fluorescent cells were counted per sample.
R esults E ffects of m eth yl-β-cyclo dextrin on cell gro w th
In order to measure Raw264.7 macrophages growth following treatment with varying levels of methyl-β-cyclodextrin, both cell counts and [
3 H]-thymidine uptake into cells were used. A close correlation was observed between cell count and [
3 H]thymidine uptake experiments. Methyl-β-cyclodextrin at doses of less than 1 mM did not reduce macrophage cell growth. In the absence of other cofactors, increasing concentrations of methyl-β-cyclodextrin above 1 mM resulted in a significant decrease in cell growth in a dosedependent manner. Methyl-β-cyclodextrin caused inhi- 
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bition of cell growth after 12 h treatment and the growth inhibition was sustained (Figure 1 ). For the analysis of cell cycle distribution affected by methyl-β-cyclodextrin treatment, the treated cells was first stained with propidium iodide and FACS analysis was carried out. Methyl-β-cyclodextrin-treated cells were associated with a significant decrease in the S+G2M phase population and an increase in the G0/G1 population in comparison with those of untreated cells in a dose-dependent manner (Figure 2) .
To determine whether these changes in cell cycle arrest were related to expressional differences of cell cycle regulatory proteins, Western blotting of cell lysates was carried out using the antibodies of various cell cycle-related proteins. Among these, cyclin A was found to be reduced by methyl-β-cyclodextrin treatment in a dose-and time-dependent manner ( Figure 3 ). In addition, the expressions of cyclin D1 and D3 were also reduced significantly by methyl-β-cyclodextrin (data not shown). However, the expression of the cdk2 was unaffected by methyl-β-cyclodextrin treatment.
M ethyl-β-cyclodextrin induces C O X -2 exp ression and P G E 2 pro duction in R aw 264.7 cells
The possible effects of methyl-β-cyclodextrin on PGE2 production in Raw264.7 cells were examined by EIA method. The data in Figure 4A and B shows that methyl-β-cyclodextrin caused dose-and time-dependent increases in PGE2 production. These changes in PGE2 synthesis were accompanied by increased expression of COX-2, as shown in the Western blotting of cell lysates ( Figure 4A and B). Neither COX-1 nor hsp70 expression was altered by methyl-β-cyclodextrin. Thus, the effects of methyl-β-cyclodextrin on (B) Cells were treated with 6 mM methyl-β-cyclodextrin for the indicated times, and total lysates were extracted. The lysates were then subjected to immunoblotting analysis, and PGE2 levels in medium were measured at the times indicated. Three independent experiments were performed, and similar results were obtained. (C) Cells were transiently transfected with the cDNA of COX-2 promoter and then stimulated with methyl-β-cyclodextrin for 12 h. The luciferase activity was measured, as described in Materials and Methods. Results are expressed relative to the luciferase activity detected in non-treated controls.
1 PGE2 synthesis were definitively mediated by COX-2.
To pursue a path of COX-2 regulation by methyl-β-cyclodextrin treatment on cells, the effect on COX-2 transcription were explored. Cells were transfected with a reporter plasmid, in which luciferase was driven by the COX-2 promoter. As shown in Figure 4C , transfection of COX-2 promoter induced a marked concentration-dependent increase in activity. The maximal increase in relative luciferase activity was 4-fold in methyl-β-cyclodextrin treated cells versus controls. To confirm that methyl-β-cyclodextrin regulated COX-2 transcriptional mechanism, we treated the cells with methyl-β-cyclodextrin after pretreating with actinomycin D for 1 h. Actinomycin D, an inhibitor of RNA synthesis, suppressed the COX-2 expression induced by methyl-β-cyclodextrin.
A P G E 2-in dependent m echanism is involved in cell grow th arrest by C O X -2
The down-regulation of cyclin A and D proteins was found to be closely correlated with methyl-β-cyclodextrin growth inhibition in Raw264.7 cells. To further explore-induced the involvement of PGE2 in methyl-β-cyclodextrin-induced growth inhibition of macrophages expressing COX-2 protein, we examined the kinetics of the system with respect to cell number, cyclin expression, and cell cycle after cells had been exposed to NS398 or indomethacin. As shown in Figure 5 , the pretreatment of cells with 10 µM of NS398, a COX-2 specific inhibitor did not affect cell growth inhibition induced by the methyl-β-cyclodextrin but resulted in the near complete inhibition of PGE2 synthesis. In addition, the attenuation of methyl-β-cyclodextrin-induced cyclin A expression and of the cell cycle was 
D iscussion
In the present study, methyl-β-cyclodextrin was found to induce G1 growth arrest in macrophages associated with an inhibition in the expression of cyclin A. In addition, methyl-β-cyclodextrin induces COX-2 expression and PGE2 production. These findings are consistent with the previous reports that cyclin A plays a major role in the cell growth. However, methyl-β-cyclodextrin-mediated growth arrest does not require the synthesis of PGE2.
It has previously been reported that methyl-β-cyclodextrin significantly inhibits cell growth (Grosse et al., 1998) , although the detailed mechanisms of this growth inhibition are unclear. To elucidate the molecular mechanism of growth inhibition by methyl-β-cyclodextrin, both cell number and [
3 H]thymidine incorporation experiment were carried out and assuredly established that this molecule caused arrest of cell growth. In addition, to investigate whether cell cycle arrest plays a role in the anti-proliferative effects of methyl-β-cyclodextrin, Raw264.7 cells were subjected to FACS analysis after methyl-β-cyclodextrin treatment. Alterations in the cell growth of Raw264.7 cells in response to methyl-β-cyclodextrin treatment were found to be associated with changes in the G1 and S phases of cell cycle. Methyl-β-cyclodextrin-treated macrophages accumulated at G1, and showed reduced [
3 H]thymidine incorporation. A clear anti-proliferative effect of methyl-β-cyclodextrin shown in Raw264.7 cells is likely associated with its affinity for cell membrane lipid components, particularly cholesterol, which plays a major role in the structure and function of the cell membrane (Jadot et al., 2001; Steck et al., 2002) . Also methyl-β-cyclodextrin, a cyclic oligosaccharide is known to interact with the lipid components of biological membranes, and to modulate their fluidities and permeabilities (Hartel et al., 1998) .
Cyclins control the transitions between the phases of the cell cycle as regulatory subunits of the cdks. Cyclin A levels increase at the G1-S boundary and reach peak levels in S phase (Pines, 1993; Hong et al., 2002) . Work by several investigators has also demonstrated that the genes of D-type cyclins regulate the rate of progression through G1 (Sherr, 1995; Coqueret, 2002) . Moreover, the inhibition of cell growth has been associated with the down-regulation of cyclin D1, with little effect on cdk4 or cyclin D3 levels (Trifan et al., 1999) . Cyclin A and D were critical targets of proliferative signals following the growth factor stimulation of quiescent cells, and their inhibition can cause a G1 arrest (Kim et al., 2003) . Our results demonstrate that cyclin A and D1 protein levels are significantly attenuated in methyl-β-cyclodextrin-treated cells, whereas the cdks levels, including those of cdk2 and cdk4, did not change in cells. Therefore, cyclin A and D1 seem to perform a crucial role in regulating the progression of macrophages through the first gap of the cell cycle. These results can be drawn to conclude that cyclin A and D1 expressions have a major role in the cell cycle arrest triggered by methyl-β-cyclodextrin.
Methyl-β-cyclodextrin induces COX-2 expression in macrophages. It remains to be determined whether growth arrest by methyl-β-cyclodextrin was linked to COX-2 expression and PGE2 production. To assess the specificity of G1 arrest subsequent to the overexpression of COX-2, a control experiment was carried out by overexpressing COX-2 protein in HEK293 cells. When COX-2 was overexpressed in the HEK293 cells, cell growth was decreased compare to that of the vector transfected control cells (data not shown). From these results, COX-2 product PGE2 may not be ruled out in its effect on the cell growth. Therefore, we next determined whether PGE2 secretion by COX-2 is necessary for the cell cycle arrest caused by methyl-β-cyclodextrin. The COX-2 inhibitor, NS398 treatment resulted in complete inhibition of PGE2 secretion by methyl-β-cyclodextrin-treated cells. However, pretreatment of cells with NS398 did not affect cell cycle arrest or cyclin A down-regulation by methyl-β-cyclodextrin. These results suggest that PGE2 is not required in the methyl-β-cyclodextrin-mediated cell cycle arrest. Generally, the expression of COX-2 is associated with a variety of proliferative diseases, such as rheumatoid arthritis, colorectal cancer, and gastric cancer (Dubois et al., 1998; Zha et al., 2001) . In addition, it is generally accepted that the COX-2 expression leads to the secretion of prostanoids including PGE2. Trifan et al. (1999) reported that interactions between secreted prostanoids and membrane receptors trigger proliferative effects and the sustained overexpression of COX-2 induces growth arrest. However, interestingly, the ability of methyl-β-cyclodextrin to induce growth arrest is independent of PGE2 secretion. This is consistent with the fact that interleukin-1 and PMA-induced endothelial cell growth arrest is not reversed by the nonsteroidal anti-inflammatory drugs that block prostanoid synthesis (Ristimaki et al., 1994) and with the finding that COX-2 overexpression induces G1 growth arrest by a hitherto uncharacterized nonprostanoid-dependent signaling pathway (Trifan et al., 1999) . Further studies are required to define this novel mechanism of COX-2 function at a molecular level, and to assess its physiological relevance.
